A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer-Reference-Cited by-同舟云学术

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Published:2015-06 Issue:6 Volume:26 Page:1194-1200
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Deplanque G.,Demarchi M.,Hebbar M.,Flynn P.,Melichar B.,Atkins J.,Nowara E.,Moyé L.,Piquemal D.,Ritter D.,Dubreuil P.,Mansfield C.D.,Acin Y.,Moussy A.,Hermine O.,Hammel P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/6/1194/16699942/mdv133.pdf

Reference12 articles.

1. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer;Heinemann;BMC Cancer,2008

2. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model;Humbert;PLoS ONE,2010

5. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer;Mitry;Cancer Chemother Pharmacol,2010

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment;Cell Death & Disease;2024-09-06

2. Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event;Cancers;2024-07-24

3. Liver Diseases: From Bench to Bedside;International Journal of Molecular Sciences;2024-05-17

4. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis;Heliyon;2024-04

5. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness;Drug Resistance Updates;2024-03